Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Hypertrophic Cardiomyopathy: early-phase trial registry

6 of 12 indexed Hypertrophic Cardiomyopathy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 6 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Hypertrophic Cardiomyopathy: 12 US clinical trials tracked, 6 recruiting.

Hypertrophic Cardiomyopathy is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 2 of these trials.

Enrollment posture brief

Registry condition hypertrophic-cardiomyopathy

OPEN 6 | RECR 50% | LATE 0 | EARLY 2 | RANK #1429 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Hypertrophic Cardiomyopa (th…50%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy lists 6 open slots (50% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hypertrophic Cardiomyopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hypertrophic Cardiomyopathy is recruiting above its size-band peers.

    6 of 12 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hypertrophic Cardiomyopathy research.

    Mayo Clinic accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hypertrophic Cardiomyopathy enrolment sits around 260 participants.

    Median target enrolment is 260 among the 11 trials that report a genuine target (sentinel values excluded). 3 of those (27.3%) plan for fewer than 100 participants.

  4. Hypertrophic Cardiomyopathy research leans observational.

    3 interventional and 9 observational studies make up this index (25% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Open and recent trials

12 total, page 1 of 1

RECRUITING 5,000 participants

Cardiovascular Multimodality Imaging Study

Montefiore Medical Center

NCT06610019

RECRUITING 500 participants

VIZ ACCESS HCM - Multi-Site Registry

Viz.ai

NCT07103057

RECRUITING 300 participants

Pediatric Cardiomyopathy Mutation Analysis

Indiana University

NCT02432092

RECRUITING NA 70 participants

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

University of California, San Francisco

NCT05818605

RECRUITING Phase 1 30 participants

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Tenaya Therapeutics

NCT05836259

RECRUITING 20 participants

Mavacamten Pregnancy Surveillance Program

Bristol-Myers Squibb

NCT05939700

ACTIVE NOT RECRUITING 2,750 participants

HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

University of Virginia

NCT01915615

ACTIVE NOT RECRUITING 260 participants

A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy

Mayo Clinic

NCT04112290

ACTIVE NOT RECRUITING 183 participants

A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's

Mayo Clinic

NCT06290570

ACTIVE NOT RECRUITING Phase 2 100 participants

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Edgewise Therapeutics

NCT06347159

COMPLETED 4,299 participants

Exercise in Genetic Cardiovascular Conditions

Yale University

NCT02549664

COMPLETED

Screening for Inherited Heart Disease

National Heart, Lung, and Blood Institute (NHLBI)

NCT00001746

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on Hypertrophic Cardiomyopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AliveCor KardiaMobile 6-Lead ECG Diagnostic test
1 trials
Apple Smart Watch Single Lead ECG Diagnostic test
1 trials
12-Lead ECG Diagnostic test
1 trials
None - this is an observational study Other
1 trials
TN-201 Genetic
1 trials
Mavacamten Drug
1 trials
Moderate Intensity Exercise Program Behavioral
1 trials
Viz HCM Device
1 trials

US sites by state

Facility locations filed on Hypertrophic Cardiomyopathy trials. A trial with sites in several states counts in each.

Minnesota 5 trials
Pennsylvania 4 trials
Ohio 4 trials
New York 4 trials
Massachusetts 4 trials
California 4 trials
Oregon 3 trials
North Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hypertrophic Cardiomyopathy page

12 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 6 Hypertrophic Cardiomyopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mayo Clinic sponsors the most Hypertrophic Cardiomyopathy trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypertrophic Cardiomyopathy condition card totals 12 registered trials; most-linked intervention AliveCor KardiaMobile 6-Lead ECG; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.